- Home
- SKYE vs THTX Comparison
SKYE vs THTX Comparison
Compare SKYE & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- THTX
- Stock Information
- Founded
- SKYE 2012
- THTX 1993
- Country
- SKYE United States
- THTX Canada
- Employees
- SKYE N/A
- THTX N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- THTX Health Care
- Exchange
- SKYE Nasdaq
- THTX Nasdaq
- Market Cap
- SKYE 115.9M
- THTX 119.1M
- IPO Year
- SKYE N/A
- THTX N/A
- Fundamental
- Price
- SKYE $3.98
- THTX $3.15
- Analyst Decision
- SKYE Buy
- THTX Hold
- Analyst Count
- SKYE 6
- THTX 1
- Target Price
- SKYE $16.60
- THTX N/A
- AVG Volume (30 Days)
- SKYE 2.2M
- THTX 1.0M
- Earning Date
- SKYE 08-08-2025
- THTX 07-09-2025
- Dividend Yield
- SKYE N/A
- THTX N/A
- EPS Growth
- SKYE N/A
- THTX N/A
- EPS
- SKYE N/A
- THTX N/A
- Revenue
- SKYE N/A
- THTX $84,378,000.00
- Revenue This Year
- SKYE N/A
- THTX N/A
- Revenue Next Year
- SKYE N/A
- THTX $15.13
- P/E Ratio
- SKYE N/A
- THTX N/A
- Revenue Growth
- SKYE N/A
- THTX 2.19
- 52 Week Low
- SKYE $1.14
- THTX $1.12
- 52 Week High
- SKYE $7.47
- THTX $3.20
- Technical
- Relative Strength Index (RSI)
- SKYE 60.88
- THTX 73.35
- Support Level
- SKYE $3.65
- THTX $2.28
- Resistance Level
- SKYE $4.75
- THTX $3.20
- Average True Range (ATR)
- SKYE 0.71
- THTX 0.07
- MACD
- SKYE 0.00
- THTX 0.08
- Stochastic Oscillator
- SKYE 48.55
- THTX 94.79
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.